Sign Out
Susceptible Organism: Co-Amoxiclav (COBIOMAX) is bactericidal to a wide range of Gram-positive and Gram-negative organisms including many clinical Important β-lactamase producing penicillin resistant pathogens: Staphylococcus epidermis, Streptococcus pyogenes, Streptococcus pneumonia, Streptococcus viridans, Streptococcus faecalis, Listeria monocytogenes, Bacillus anthracis, Corynebacterium species, Clostridium species, Peptococcus species, Peptostreptococcus species, Cachirichia coli, Proteus mirabilis, Proteus vulgaris, Klebsiella species, Salmonella species, Bordotella pertussis, Haemophilus influenza, Brucella species, Neisseria meningtidis, Neisseria gonorrhoea, Yersinia enterocolitica, Gardnerella vaginalis, Branhamella catarrhalis, Haemophilus ducreyi, Pasteuralla multocida, Campylobacter leiuni, Vibrio choleae, Bacteroides species including Bacteroides fragilis (including β-lactamase producing strains resistant to ampicillin and amoxicillin).
Co-Amoxiclav (COBIOMAX) is indicated in the treatment of common bacterial infections where antibiotics therapy is indicated, including: Tonsilitis, Sinusitis, Otitis Media, acute and chronic bronchitis, pneumonia, thoracic emphysema, lung abscess, boils and abscesses, cellulites, wound infection, intra-abdominal sepsis, cystitis, urethritis, nephropyelitis, septic abortion, pelvic infection, chancroid, gonorrhea, osteomyelitis.
Continue with Google